Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%

Healthcare

Page 92
  1. Dec 02, 2025 · 07:30 · BCT

    BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS(TM) 2025

    BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS(TM) 2025

    01
  2. Dec 02, 2025 · 07:01 · FRX

    Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK(TM) in Japan to Reduce Cisplatin-Induced Hearing Loss

    Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK(TM) in Japan to Reduce Cisplatin-Induced Hearing Loss

    02
  3. Dec 02, 2025 · 07:00 · NURS

    Hydreight Technologies Announces Corporate Update Highlighting Q3 Momentum, VSDHOne Acceleration, and 2026 Outlook

    Hydreight Technologies Announces Corporate Update Highlighting Q3 Momentum, VSDHOne Acceleration, and 2026 Outlook

    03
  4. Dec 02, 2025 · 07:00 · VST

    Hydreight Technologies Announces Corporate Update Highlighting Q3 Momentum, VSDHOne Acceleration, and 2026 Outlook

    Hydreight Technologies Announces Corporate Update Highlighting Q3 Momentum, VSDHOne Acceleration, and 2026 Outlook

    04
  5. Dec 01, 2025 · 22:29 · VST

    Victory Square Technologies Reports Q3 2025 Financial Results & Provides Corporate Update

    Victory Square Technologies Reports Q3 2025 Financial Results & Provides Corporate Update

    05
  6. Dec 01, 2025 · 18:00 · 4875

    Message from the CEO to MediciNova Shareholders

    Message from the CEO to MediciNova Shareholders

    06
  7. Dec 01, 2025 · 17:45 · MVMD

    Mountain Valley MD Confirms Positive Agrarius Agricultural Trial Results, Advancing Toward Commercialization

    Mountain Valley MD Confirms Positive Agrarius Agricultural Trial Results, Advancing Toward Commercialization

    07
  8. Dec 01, 2025 · 17:05 · CSCI

    COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen(TM) in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore

    COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen(TM) in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore

    08
  9. Dec 01, 2025 · 16:22 · BHC

    Bausch Health closes Wuhan Shibo acquisition

    Bausch Health closes Wuhan Shibo acquisition

    09
  10. Dec 01, 2025 · 15:37 · RKV

    Rakovina's Q3 R&D expenses at $1.1-million

    Rakovina's Q3 R&D expenses at $1.1-million

    10
  11. Dec 01, 2025 · 14:42 · BNXT

    Bionxt to acquire IP to sublingual drug formulation

    Bionxt to acquire IP to sublingual drug formulation

    11
  12. Dec 01, 2025 · 13:45 · KDA

    KDA GROUP DEPLOYS MEDHERIZE ACROSS COMMUNITY PHARMACIES: A MAJOR STEP FORWARD IN THE MANAGEMENT OF ORAL ANTICANCER THERAPIES

    KDA GROUP DEPLOYS MEDHERIZE ACROSS COMMUNITY PHARMACIES: A MAJOR STEP FORWARD IN THE MANAGEMENT OF ORAL ANTICANCER THERAPIES

    12
  13. Dec 01, 2025 · 07:28 · CRDL

    New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

    New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

    13
  14. Nov 28, 2025 · 21:00 · MIR

    MedMira Reports FY2025 Fourth Quarter and Year End Financial Results

    MedMira Reports FY2025 Fourth Quarter and Year End Financial Results

    14
← Newer Older →